Publications 1977-2022

DIRAS3 Induces Autophagy and Enhances Sensitivity to Anti-Autophagic Therapy in KRAS-Driven Pancreatic and Ovarian Carcinomas
Bildik G, Gray J, Mao W, Yang H, Ozyurt R, Orellana VR, De Wever O, Carey MS, Bast RC Jr, Lu Z. 2024 Jan 3. doi: 10.1080/15548627.2023.2299516

A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do AK, Drescher C, Lu K, Lu Z, Bast RC Jr, Hanashm S, Fahrmann JF. 2022 Nov 1;28(21):4669-4676. doi: 10.1158/1078-0432.CCR-22-1113

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
Handley KF, Sims TT, Batemanm NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Jinsong L, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin S, Celestino J, Rangel KM, Badal S, Pereira I, Ram P, Maxwell GL, Eberlin LS, Futreal PA, Bast RC Jr, Fleming ND, Conrads TP, Sood AK. 2022 Oct 3;5(10):e2236626. doi: 10.1001/jamanetworkopen.2022.36626.

Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy
Brown H, Chung M, Üffing A, Batistatou N, Tsang T, Doskocil S, Mao W, Willbold D, Bast RC Jr, Lu Z, Weiergräber OH, Kritzer JA. 2022 Aug 17;144(32):14687-14697. doi: 10.1021/jacs.2c04699.

SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK
Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC Jr, Lu Z, Guo L, Chen Y, Zhou J. 2022 Jul;16(13):2558-2574. doi: 10.1002/1878-0261.13208.

Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer
Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC Jr, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. 2022 Jun 23;14(13):3077. doi: 10.3390/cancers14133077.

Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display
Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC Jr, Curran MA, Takahashi TT, Roberts RW, Millward SW. 2022 Jun 17;17(6):1543-1555. doi: 10.1021/acschembio.2c00218.

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Che F, Alsaadi A, Albukhari A, Fotso FC, Yau C, Jiang D, Pradeep S, Rodriguz-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D,  Bast RC Jr, Sood AK, VonDelf F, Ahmed AA. 2022 Jun 10;13(1):3352. doi: 10.1038/s41467-022-31011-1.

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471. PMID: 35642638; PMCID: PMC9151707.

One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates
Kim CS, Nevozhay D, Aburto RR, Pehere A, Pang L, Dillard R, Wang Z, Smith C, Mathieu KB, Zhang M, Hazle JD, Bast RC Jr, Sokolov K. One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates. Bioconjug Chem. 2022 May 18;33(5):969-981. doi: 10.1021/acs.bioconjchem.2c00167. Epub 2022 May 6. PMID: 35522527; PMCID: PMC9121875.

DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy
Bildik G, Liang X, Sutton MN, Bast RC Jr, Lu Z. DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. Mol Cancer Ther. 2022 Jan;21(1):25-37. doi: 10.1158/1535-7163.MCT-21-0331. Epub 2021 Oct 19. PMID: 34667114.

Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors
Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller MC, Moore RG. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biol. 2021 Dec 21;43(1):355-365. doi: 10.3233/TUB-211546. PMID: 34957977.

IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming
Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 2021 Sep 29;10(9):65. doi: 10.1038/s41389-021-00349-4. PMID: 34588424; PMCID: PMC8481288.

Next steps in the early detection of ovarian cancer
Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Commun Med (Lond). 2021;1:36. doi: 10.1038/s43856-021-00037-9. Epub 2021 Oct 5. PMID: 34676377; PMCID: PMC8525879.

Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer
Han CY, Patten DA, Kim SI, Lim JJ, Chan DW, Siu MKY, Han Y, Carmona E, Parks RJ, Lee C, Di LJ, Lu Z, Chan KKL, Ku JL, Macdonald EA, Vanderhyden BC, Mes-Masson AM, Ngan HYS, Cheung ANY, Song YS, Bast RC Jr, Harper ME, Tsang BK. Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Jul 7;13(14):3399. doi: 10.3390/cancers13143399. PMID: 34298618; PMCID: PMC8306240.

Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
Niu N, Shen W, Zhong Y, Bast RC Jr, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol. 2021 Jul;113:20-27. doi: 10.1016/j.humpath.2021.04.003. Epub 2021 Apr 19. PMID: 33887301; PMCID: PMC8219231.

Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC Jr, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells. JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929. PMID: 33945502; PMCID: PMC8262282.

A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer
Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel). 2021 Feb 22;13(4):913. doi: 10.3390/cancers13040913. PMID: 33671595; PMCID: PMC7927060.

Circulating Cancer Biomarkers
Lokshin A, Bast RC, Rodland K. Circulating Cancer Biomarkers. Cancers (Basel). 2021 Feb 15;13(4):802. doi: 10.3390/cancers13040802. PMID: 33671847; PMCID: PMC7918137.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021;17(1):1-382. doi:10.1080/15548627.2020.1797280

A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin
Fan D, Yang H, Mao W, Rask PJ, Pang L, Xu C, Vankayalapat H, Ahmed AA, Bast RC Jr, Lu Z. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers (Basel). 2021 Jan 25;13(3):446. doi: 10.3390/cancers13030446. PMID: 33503955; PMCID: PMC7865895.

Directed evolution of cyclic peptides for inhibition of autophagy
Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC Jr, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci. 2021 Jan 13;12(10):3526-3543. doi: 10.1039/d0sc03603j. PMID: 34163626; PMCID: PMC8179393.

Targeting progesterone signaling prevents metastatic ovarian cancer
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC Jr, Godwin AK, Miller KD, Cho CH, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31993-32004. doi: 10.1073/pnas.2013595117. Epub 2020 Dec 1. PMID: 33262282; PMCID: PMC7749341.

The National Cancer Institute Early Detection Research Network: Two Decades of Progress
Bast RC Jr, Srivastava S. The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2396-2400. doi: 10.1158/1055-9965.EPI-20-1158. PMID: 33262198; PMCID: PMC7717495.

Biomarkers and Strategies for Early Detection of Ovarian Cancer
Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512. doi: 10.1158/1055-9965.EPI-20-1057. Epub 2020 Oct 13. PMID: 33051337; PMCID: PMC7710577.

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3. Erratum in: Clin Cancer Res. 2022 Sep 15;26(18):5050. PMID: 30084832; PMCID: PMC6191368.

Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr. Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2020 Sep 15;26(18):5050. doi: 10.1158/1078-0432.CCR-20-3198. Erratum for: Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. PMID: 32934031.

Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition
Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC Jr. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer. 2020 Aug 1;126(15):3579-3592. doi: 10.1002/cncr.32985. Epub 2020 Jun 2. PMID: 32484926; PMCID: PMC7384209

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC Jr, Jacobs IJ, Zaikin A, Menon U. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers (Basel). 2020 Jul 17;12(7):1931. doi: 10.3390/cancers12071931. PMID: 32708856; PMCID: PMC7409061.

In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC Jr, Miller KD, Karpf AR, Kim J. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet. 2020 Jun 4;16(6):e1008808. doi: 10.1371/journal.pgen.1008808. PMID: 32497036; PMCID: PMC7297383.

Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders
Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC Jr, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12121-12130. doi: 10.1073/pnas.2000848117. Epub 2020 May 18. PMID: 32424096; PMCID: PMC7275768.

SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters
Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC Jr, Feng W. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Int J Cancer. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30. PMID: 31503345.

Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis
Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC Jr, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel). 2020 Feb 19;12(2):485. doi: 10.3390/cancers12020485. PMID: 32092936; PMCID: PMC7072578.

Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer
Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC Jr. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer. 2020 Feb 15;126(4):725-736. doi: 10.1002/cncr.32582. Epub 2019 Nov 12. PMID: 31714597; PMCID: PMC6992519.

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC Jr. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer. 2020 Feb 15;126(4):894-907. doi: 10.1002/cncr.32600. Epub 2019 Nov 12. PMID: 31714594; PMCID: PMC6992526.

DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters
Sutton MN, Lu,Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Liang X, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC Jr. DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Rep. 2019 Dec 10;29(11):3448-3459.e6. doi: 10.1016/j.celrep.2019.11.045. PMID: 31825828; PMCID: PMC6948147.

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers
Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res. 2019 Sep 15;25(18):5702-5716. doi: 10.1158/1078-0432.CCR-18-3448. Epub 2019 Aug 7. PMID: 31391192; PMCID: PMC6744996.

Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer
Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol. 2019 Sep;10(5):705-708. doi: 10.1016/j.jgo.2019.01.024. Epub 2019 Feb 19. PMID: 30795923; PMCID: PMC6699920.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. J Clin Oncol. 2019 Aug 1;37(22):1956-1964. doi: 10.1200/JCO.19.00945. Epub 2019 May 31. PMID: 31150316.

Novel Approaches to Ovarian Cancer Screening
Nebgen DR, Lu KH, Bast RC Jr. Novel Approaches to Ovarian Cancer Screening. Curr Oncol Rep. 2019 Jul 26;21(8):75. doi: 10.1007/s11912-019-0816-0. PMID: 31346778; PMCID: PMC6662655.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. PMID: 30835824; PMCID: PMC6557260.

Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC Jr. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prev Res (Phila). 2019 Jun;12(6):391-400. doi: 10.1158/1940-6207.CAPR-18-0377. Epub 2019 Apr 9. PMID: 30967390; PMCID: PMC6548633.

Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression
Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC Jr. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers (Basel). 2019 Apr 30;11(5):603. doi: 10.3390/cancers11050603. PMID: 31052266; PMCID: PMC6562629.

Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC Jr. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers (Basel). 2019 Apr 28;11(5):596. doi: 10.3390/cancers11050596. PMID: 31035430; PMCID: PMC6562667.

DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1
Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, Bast RC Jr. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers (Basel). 2019 Apr 18;11(4):557. doi: 10.3390/cancers11040557. PMID: 31003488; PMCID: PMC6521623.

The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts
Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC Jr. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer. 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8. PMID: 30620384; PMCID: PMC6538072.

Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection
Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC Jr, Lu KH, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila). 2019 Mar;12(3):171-184. doi: 10.1158/1940-6207.CAPR-18-0221. Epub 2019 Feb 1. PMID: 30709840; PMCID: PMC6410372. 

Targeting progesterone signaling prevents metastatic ovarian cancer
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC Jr, Godwin AK, Miller KD, Cho CH, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31993-32004. doi: 10.1073/pnas.2013595117. Epub 2020 Dec 1. PMID: 33262282; PMCID: PMC7749341.

Cell Origins of High-Grade Serous Ovarian Cancer
Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. PMID: 30424539; PMCID: PMC6267333.

Early Detection of Ovarian Cancer
Elias KM, Guo J, Bast RC Jr. Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am. 2018 Dec;32(6):903-914. doi: 10.1016/j.hoc.2018.07.003. Epub 2018 Sep 28. PMID: 30390764; PMCID: PMC6376972.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11. PMID: 30311036.

Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT.
Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC Jr, Millward SW. Bioconjug Chem. 2018 Sep 19;29(9):3180-3195. PMID: 30168713

Potentially inappropriate medication use in older patients with breast and colorectal cancer
Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC Jr, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer. 2018 Jul 15;124(14):3000-3007. doi: 10.1002/cncr.31403. Epub 2018 Apr 24. PMID: 29689595; PMCID: PMC6033638.

Screening for ovarian cancer: imaging challenges and opportunities for improvement
Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC Jr. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303. doi: 10.1002/uog.17557. PMID: 28639753; PMCID: PMC5788737.

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr, Sood AK, von Delft F, Ahmed AA. Nat Commun. 2018 Feb 2;9(1):476.  PMID: 29396402

RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells.
Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC Jr. Autophagy. 2018;14(4):637-653.  PMID: 29368982

In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes
Lin CW, Yang H, Sanchez SR, Mao W, Pang L, Beckingham KM, Bast RC Jr, Weisman RB. In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. ACS Appl Mater Interfaces. 2017 Dec 6;9(48):41680-41690. doi: 10.1021/acsami.7b12916. Epub 2017 Nov 27. PMID: 29131572.

Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr; AOCS Study Group. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res. 2017 Oct 1;23(19):5912-5922. doi: 10.1158/1078-0432.CCR-17-0284. Epub 2017 Jun 21. PMID: 28637689; PMCID: PMC5626590.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017 Aug 20;35(24):2838-2847. doi: 10.1200/JCO.2017.74.0472. Epub 2017 Jul 10. PMID: 28692382; PMCID: PMC5846188.

The role of biomarkers in the management of epithelial ovarian cancer
Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017 Jun;17(6):577-591. doi: 10.1080/14737159.2017.1326820. Epub 2017 May 15. PMID: 28468520; PMCID: PMC5823503.

A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel
Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC Jr. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clin Cancer Res. 2017 Apr 15;23(8):1945-1954. doi: 10.1158/1078-0432.CCR-16-1562. Epub 2016 Sep 27. PMID: 27678456; PMCID: PMC5436602.

Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.
Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC Jr, Ahmed AA. Oncotarget. 2017 Mar 14;8(11):17960-17980.  PMID: 28152500

Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression
Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC Jr, Merchant FA, Coarfa C, Frigo DE. Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 2017 Mar 4;13(3):506-521. doi: 10.1080/15548627.2016.1268300. Epub 2016 Dec 15. PMID: 27977328; PMCID: PMC5361609.

Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC Jr, Millward SW.
BMC Cancer. 2016 Oct 26;16(1):824. PMID: 27784287

Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, Davis G, Serra S, Diamandis EP, Kulasingam V.
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. PMID: 27448593

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC Jr, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA.
Cancer Cell. 2016 Aug 8;30(2):273-289. PMID: 27478041

Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
EBioMedicine. 2016 Aug;10:137-49. PMID: 27492892

Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC Jr, Skates SJ.
Int J Gynecol Cancer. 2016 Jul;26(6):1070-7. PMID: 27206285

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology.
J Clin Oncol. 2016 Apr 1;34(10):1134-50. Review. PMID: 26858339

Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC Jr, Carson DD.
Oncotarget. 2016 Mar 22;7(12):14871-84. PMID: 26918940

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.
Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.
Mol Cell. 2016 Feb 18;61(4):520-534. Erratum in: Mol Cell. 2016 Feb 18;61(4):640. PMID: 26853146

NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC Jr.
Oncotarget. 2016 Jan 19;7(3):3018-32. PMID: 26689988

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.
Int J Gynecol Cancer. 2016 Jan;26(1):43-51. PMID: 26588231

Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.
Ma Y, Wei Z, Bast RC Jr, Wang Z, Li Y, Gao M, Liu Y, Wang X, Guo C, Zhang L, Wang X.
Lab Invest. 2016 Jan;96(1):37-48. PMID: 26568293

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.
Nat Rev Cancer. 2015 Nov;15(11):668-79. Review. PMID: 26493647

ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC Jr, Lu Z.
Cell Death Dis. 2015 Aug 6;6:e1836. PMID: 26247722

CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC Jr.
PLoS One. 2015 Jul 6;10(7):e0131833. PMID: 26146988

How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?
Pickering CR, Bast RC Jr, Keyomarsi K.
Cancer. 2015 Mar 15;121(6):806-16. Review. PMID: 25355050

Clinically relevant microRNAs in ovarian cancer.
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC Jr, Le XF.
Mol Cancer Res. 2015 Mar;13(3):393-401. Review. PMID: 25304686

A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC Jr, McDevitt JT.
Cancer Prev Res (Phila). 2015 Jan;8(1):37-48. PMID: 25388014

Variant prostate carcinoma and elevated serum CA-125.
Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R Jr, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Can J Urol. 2014 Oct;21(5):7442-8. PMID: 25347368

ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.
Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC Jr. Cell Death Differ. 2014 Aug;21(8):1275-89. PMID: 24769729

DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.
Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC Jr. Autophagy. 2014 Jun;10(6):1071-92. Erratum in: Autophagy. 2014 Aug;10(8):1482. PMID: 24879154

Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening.
Holman LL, Lu KH, Bast RC Jr, Hernandez MA, Bodurka DC, Skates S, Sun CC. Am J Obstet Gynecol. 2014 Mar;210(3):257.e1-6. PMID: 24246524

Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.
Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC Jr, Hua K, Feng W. Epigenetics. 2013 Dec;8(12):1330-46. PMID: 24135786

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr. Cancer. 2013 Oct 1;119(19):3454-61. PMID: 23983047

Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.
Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC Jr, Wan X, Xi X, Feng Y. Int J Oncol. 2013 Oct;43(4):1194-204. PMID: 23921511

Low-grade serous carcinoma: new concepts and emerging therapies.
Romero I, Sun CC, Wong KK, Bast RC Jr, Gershenson DM. Gynecol Oncol. 2013 Sep;130(3):660-6. Review. PMID: 23707670

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J. Int J Gynecol Cancer. 2013 Jun;23(5):815-22. PMID: 23669443

The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR, Baggerly K, Bast RC Jr. Oncology (Williston Park). 2013 Jun;27(6):548-56. Review. PMID: 23909069

FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.
Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC Jr, Yu Y, Feng Y. Endocr Relat Cancer. 2013 May 30;20(3):415-29. PMID: 23580589

Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2018 Feb 9;8:9. doi: 10.3389/fonc.2018.00009. Erratum for: Front Oncol. 2013 Mar 20;3:58. PMID: 29456965; PMCID: PMC5811641.

Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK. Front Oncol. 2013 Mar 20;3:58. Erratum in: Front Oncol. 2018 Feb 09;8:9. PMID: 23519775

The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms.
Lu Z, Bast RC Jr. Cell Adh Migr. 2013 Mar-Apr;7(2):232-6. PMID: 23357870

Conquering cancer in our lifetime: new diagnostic and therapeutic trends.
Diamandis EP, Bast RC Jr, Lopez-Otín C. Clin Chem. 2013 Jan;59(1):1-3. PMID: 23204223

Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.
Diamandis EP, Bast RC Jr, Gold P, Chu TM, Magnani JL. Clin Chem. 2013 Jan;59(1):22-31. PMID: 23204222

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W.
Cancer Biol Ther. 2012 Sep;13(11):1034-41. PMID: 22895067

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB.
Gynecol Oncol. 2012 Jul;126(1):47-53. PMID: 22487539

Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, Hilsenbeck SG, Yu Y.
BMC Cancer. 2012 Jun 13;12:243. PMID: 22695491

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA.
Cancer. 2012 May 15;118(10):2603-14. PMID: 22370716

Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.
Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC Jr, McDevitt JT.
Cancer Prev Res (Phila). 2012 May;5(5):706-16. PMID: 22490510

Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.
Bast RC Jr, Skates S, Lokshin A, Moore RG.
Int J Gynecol Cancer. 2012 May;22 Suppl 1:S5-8. PMID: 22543921

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G.
Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7. PMID: 22301440

Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC Jr.
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. PMID: 22284961

Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.
Romero I, Bast RC Jr.
Endocrinology. 2012 Apr;153(4):1593-602. Review. PMID: 22416079

The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.
Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC Jr.
Oncogene. 2012 Jan 5;31(1):68-79. PMID: 21643014

The origin of ovarian cancer.
Ahmed AA, Becker CM, Bast RC Jr.
BJOG. 2012 Jan;119(2):134-6. PMID: 22168761

Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr.
Cancer. 2012 Jan 1;118(1):91-100. PMID: 21717433

Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer.
Bast RC Jr, Mills GB.
Cancer Discov. 2012 Jan;2(1):16-8. PMID: 22585163

A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, Robertson FM, McMurray JS.
J Exp Ther Oncol. 2012;10(2):155-62. PMID: 23350355

Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC Jr.
PLoS One. 2012;7(7):e41170. PMID: 22829924

Molecular approaches to personalizing management of ovarian cancer.
Bast RC Jr.          
Ann Oncol. 2011 Dec;22 Suppl 8:viii5-viii15. Review. PMID: 22180401

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.
Cancer. 2011 Oct 1;117(19):4424-38. PMID: 21491416

A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer.
Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC Jr, Priebe W.
Cancer Chemother Pharmacol. 2011 Oct;68(4):1033-44. PMID: 21340606

Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.
Nat Rev Cancer. 2011 Sep 23;11(10):719-25. PMID: 21941283

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.
J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. PMID: 21813412

Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel.
Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC Jr.
Cancer Res. 2011 Sep 1;71(17):5806-17. PMID: 21775522

Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr.
Gynecol Oncol. 2011 Sep;122(3):548-53. PMID: 21708402

Src family kinases and paclitaxel sensitivity.
Le XF, Bast RC Jr.
Cancer Biol Ther. 2011 Aug 15;12(4):260-9. Epub 2011 Aug 15. Review. PMID: 21646863

More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis.
Bast RC Jr, Spriggs DR.
Gynecol Oncol. 2011 Jun 1;121(3):429-30. PMID: 21601106

Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC Jr, Liao WS, McMurray JS.
J Med Chem. 2011 May 26;54(10):3549-63. PMID: 21486047

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr.
Cancer. 2011 Apr 15;117(8):1661-9. PMID: 21472713

Reproducibility of SELDI Spectra Across Time and Laboratories.
Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC Jr.
Cancer Inform. 2011 Mar 14;10:45-64. PMID: 21552492

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.
Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. PMID: 21372037

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.
Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. PMID: 21372036

Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC Jr, Feng Y, Yu Y.
BMC Cancer. 2011 Jan 19;11:22. PMID: 21244707

A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies.
Hennessey VG, Rosner GL, Bast RC Jr, Chen MY.
Biometrics. 2010 Dec;66(4):1275-83. PMID: 20337630

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.
Mol Cancer Ther. 2010 Dec;9(12):3186-99. PMID: 20889728

Dasatinib induces autophagic cell death in human ovarian cancer.
Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr.
Cancer. 2010 Nov 1;116(21):4980-90. PMID: 20629079

Chemotherapy: A new standard combination for recurrent ovarian cancer?
Bast RC Jr, Markman M.
Nat Rev Clin Oncol. 2010 Oct;7(10):559-60. PMID: 20877420

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ.
Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6. PMID: 20471625

SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF; Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC Jr.
Cancer Cell. 2010 Aug 9;18(2):109-21. PMID: 20708153

Personalizing therapy for ovarian cancer: BRCAness and beyond.
Bast RC Jr, Mills GB.
J Clin Oncol. 2010 Aug 1;28(22):3545-8. PMID: 20547987

Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, Yu Y.
BMC Cancer. 2010 Jul 20;10:378. PMID: 20642860

Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells.
Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J.
Mol Med Rep. 2010 Jul-Aug;3(4):581-7. PMID: 21472283

CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
Bast RC Jr.
Cancer. 2010 Jun 15;116(12):2850-3. PMID: 20564390

Stanniocalcin 1 and ovarian tumorigenesis.
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J.
J Natl Cancer Inst. 2010 Jun 2;102(11):812-27. PMID: 20484106

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A.
Gynecol Oncol. 2010 Jun;117(3):440-5. PMID: 20334903

Combined use of biomarkers for detection of ovarian cancer in high-risk women.
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO.
Tumour Biol. 2010 Jun;31(3):209-15. PMID: 20393825

Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE.
J Clin Oncol. 2010 May 1;28(13):2159-66. PMID: 20368574

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr.
J Hematol Oncol. 2010 Mar 11;3:9. PMID: 20222977

The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade.
Le XF, Merchant O, Bast RC, Calin GA.
Cancer Microenviron. 2010 Feb 23;3(1):137-47. PMID: 21209780

Current state of biomarker development for clinical application in epithelial ovarian cancer.
Moore RG, MacLaughlan S, Bast RC Jr.
Gynecol Oncol. 2010 Feb;116(2):240-5. Review. PMID: 19879639

Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs.
Bast RC Jr.
Cancer Biomark. 2010-2011;8(4-5):161-6. PMID: 22045350

Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J.
Cell Cycle. 2010 Jan 1;9(1):140-6. Epub 2010 Jan 5. PMID: 20016289

ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins.
Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC Jr, Chen X, Yu Y.
Biosci Rep. 2009 Dec 15;30(3):159-68. PMID: 19435463

Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC Jr.
J Clin Oncol. 2009 Sep 10;27(26):4433-40. PMID: 19652061

MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC Jr, Liao WS.
Cancer. 2009 Sep 1;115(17):3897-908. PMID: 19517469

A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC.
Mol Cancer Ther. 2009 Aug;8(8):2375-82. Erratum in: Mol Cancer Ther. 2009 Sep;8(9):2771. PMID: 19671744

The biology of ovarian cancer: new opportunities for translation.
Bast RC Jr, Hennessy B, Mills GB.
Nat Rev Cancer. 2009 Jun;9(6):415-28. Review. PMID: 19461667

Tumor suppressor genes.
Lu Z, Bast RC Jr.
Cancer Treat Res. 2009;149:109-29. PMID: 19763433

Urinary levels of Bcl-2 are elevated in ovarian cancer patients.
Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA.
Gynecol Oncol. 2009 Jan;112(1):60-7. PMID: 19007973

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ.
Gynecol Oncol. 2009 Jan;112(1):40-6. PMID: 18851871

CA125/MUC16 is dispensable for mouse development and reproduction.
Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR.
PLoS One. 2009;4(3):e4675. PMID: 19262696

Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Jr.
Cell Cycle. 2008 Dec;7(23):3747-58. Epub 2008 Dec 16. PMID: 19029832

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry.
Clin Chem. 2008 Dec;54(12):e11-79. PMID: 19042984

MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR.
Differentiation. 2008 Dec;76(10):1081-92. PMID: 18637025

The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC Jr.
J Clin Invest. 2008 Dec;118(12):3917-29. PMID: 19033662

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC Jr, Hortobagyi GN, Hung MC.
Mol Carcinog. 2008 Sep;47(9):701-6. PMID: 18176935

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K.
Gynecol Oncol. 2008 Aug;110(2):196-201. PMID: 18495222

Early detection of ovarian cancer.
Das PM, Bast RC Jr.
Biomark Med. 2008 Jun;2(3):291-303. PMID: 20477415

Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr.
Cancer. 2008 Apr 1;112(7):1489-502. PMID: 18286529

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.
Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P.
Gynecol Oncol. 2008 Mar;108(3):652-7. Epub 2007 Dec 21. PMID: 18096210

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr.
Gynecol Oncol. 2008 Feb;108(2):402-8. Epub 2007 Dec 3. PMID: 18061248

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr.
Gynecol Oncol. 2007 Dec;107(3):526-31. Epub 2007 Oct 24. PMID: 17920110

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R.
Gynecol Oncol. 2007 Nov;107(2):173-6. PMID: 17950384

Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC Jr.
Mol Cancer Ther. 2007 Nov;6(11):2843-57. PMID: 18025271

How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.
Moore RG, Bast RC Jr.
J Clin Oncol. 2007 Sep 20;25(27):4159-61. Epub 2007 Aug 13. PMID: 17698803

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr.
Gynecol Oncol. 2007 Sep;106(3):490-7. Epub 2007 May 25. PMID: 17532030

Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y.
Breast Cancer Res. 2007;9(4):R57. PMID: 17764565

Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.
Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J.
Carcinogenesis. 2007 Jan;28(1):174-82. Epub 2006 Jul 8. PMID: 16829690

Early detection of ovarian cancer.
Badgwell D, Bast RC Jr.
Dis Markers. 2007;23(5-6):397-410. Review. PMID: 18057523

Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer.
Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C.
Front Biosci. 2007 Jan 1;12:2260-8. PMID: 17127462

Prevention and early detection of ovarian cancer: mission impossible?
Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y.
Recent Results Cancer Res. 2007;174:91-100. Review. PMID: 17302189

The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J.
Cancer. 2006 Dec 1;107(11):2730-40. PMID: 17063503

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF.
Oncogene. 2006 Nov 2;25(52):6986-96. Epub 2006 May 22. PMID: 16715132

Biomarkers and clinical trial design.
Farley J, Bast RC Jr, Birrer MJ.
Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S3-5. Epub 2006 Oct 5. PMID: 17027069

The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.
Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J.
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. Epub 2006 Oct 23. PMID: 17060621

4-HPR modulates gene expression in ovarian cells.
Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C.
Int J Cancer. 2006 Sep 1;119(5):1005-13. PMID: 16570282

Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S, Kavanagh JJ, Hu W, Bast RC Jr.
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1717-32. Review. PMID: 17009963

Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC Jr.
Cell Cycle. 2006 Aug;5(15):1654-61. Epub 2006 Aug 1. PMID: 16861913

Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.
Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC Jr.
Clin Cancer Res. 2006 Apr 15;12(8):2404-13. PMID: 16638845

10th Biennial Helene Harris Memorial Trust meeting.
Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND.
Cancer Res. 2006 Mar 15;66(6):2904-6. PMID: 16540635

Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X.
Cancer Res. 2006 Mar 1;66(5):2740-8. PMID: 16510595

Targeting Aurora kinases in ovarian cancer.
Fu S, Hu W, Kavanagh JJ, Bast RC Jr.
Expert Opin Ther Targets. 2006 Feb;10(1):77-85. Review. PMID: 16441230

Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
Rosen DG, Yang G, Bast RC Jr, Liu J.
Methods Enzymol. 2006;407:660-76. PMID: 16757360

Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers.
Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC Jr.
Methods Enzymol. 2006;407:455-68. PMID: 16757345

Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr.
Gynecol Oncol. 2005 Nov;99(2):267-77. Epub 2005 Aug 2. PMID: 16061277

New tumor markers: CA125 and beyond.
Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review. PMID: 16343244

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ.
J Clin Oncol. 2005 Nov 1;23(31):7919-26. PMID: 16258091

Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model.
Young T, Mei F, Liu J, Bast RC Jr, Kurosky A, Cheng X.
Oncogene. 2005 Sep 8;24(40):6174-84. PMID: 15940260

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH.
Clin Cancer Res. 2005 Sep 1;11(17):6116-26. PMID: 16144910

Translational crossroads for biomarkers.
Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A.
Clin Cancer Res. 2005 Sep 1;11(17):6103-8. Review. PMID: 16144908

A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC Jr, Luo RZ.
Cancer Res. 2005 Aug 1;65(15):6701-10. PMID: 16061651

In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C.
Gynecol Oncol. 2005 Aug;98(2):182-92. PMID: 15907982

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.
Clin Cancer Res. 2005 Mar 15;11(6):2149-55. PMID: 15788660

Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.
Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC Jr.
J Biol Chem. 2005 Jan 21;280(3):2092-104. Epub 2004 Oct 25. PMID: 15504738

Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Rosen DG, Yang G, Cai KQ, Bast RC Jr, Gershenson DM, Silva EG, Liu J.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):632-7. PMID: 15701850

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Le XF, Pruefer F, Bast RC Jr.
Cell Cycle. 2005 Jan;4(1):87-95. Epub 2005 Jan 10. Review. PMID: 15611642

Individualized care for patients with cancer - a work in progress.
Bast RC Jr, Hortobagyi GN.
N Engl J Med. 2004 Dec 30;351(27):2865-7. Epub 2004 Dec 10. PMID: 15591336

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr.
J Clin Oncol. 2004 Oct 15;22(20):4059-66. Epub 2004 Sep 20. PMID: 15381683

Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC Jr.
Clin Cancer Res. 2004 Oct 1;10(19):6559-66. PMID: 15475444

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW.
Cancer Res. 2004 Aug 15;64(16):5882-90. PMID: 15313933

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.
Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM.
Bone Marrow Transplant. 2004 Jun;33(12):1219-24. PMID: 15122311

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW.
Clin Cancer Res. 2004 Jun 1;10(11):3919-26. Review. PMID: 15173101

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Kelloff GJ, Bast RC Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF.
Clin Cancer Res. 2004 Jun 1;10(11):3881-4. Review. PMID: 15173097

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr.
Clin Cancer Res. 2004 May 15;10(10):3291-300. PMID: 15161682

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB.
J Biol Chem. 2004 Mar 5;279(10):9653-61. Epub 2003 Dec 11. PMID: 14670967

A genetically defined model for human ovarian cancer.
Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC Jr.
Cancer Res. 2004 Mar 1;64(5):1655-63. PMID: 14996724

Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
Samanta AK, Huang HJ, Bast RC Jr, Liao WS.
J Biol Chem. 2004 Feb 27;279(9):7576-83. Epub 2003 Dec 8. PMID: 14662759

Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J.
J Biol Chem. 2004 Feb 6;279(6):4339-45. Epub 2003 Nov 18. PMID: 14625284

Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC Jr, Hortobagyi GN.
Cancer Invest. 2004;22(2):248-56. PMID: 15199607

Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
Bast RC Jr.
Trans Am Clin Climatol Assoc. 2004;115:233-47; discussion 247-8. Review. PMID: 17060970

Targeted therapy for epithelial ovarian cancer: current status and future prospects.
See HT, Kavanagh JJ, Hu W, Bast RC.
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):701-34. Review. PMID: 14675307

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G.
Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. Review. PMID: 14613030

Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr, Yu Y.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3660-6. PMID: 14506155

Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45. PMID: 14506139

Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J.
Eur J Cancer. 2003 Sep;39(13):1818-27. Erratum in: Eur J Cancer. 2004 Mar;40(4):628. Ursulic S [corrected to Orsulic S]. PMID: 12932658

Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC Jr, Yu Y.
Hum Mol Genet. 2003 Aug 1;12(15):1791-800. PMID: 12874100

Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin A, Issa JP, Bast RC Jr, Yu Y.
Cancer Res. 2003 Jul 15;63(14):4174-80. PMID: 12874023

Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC Jr, Zhang X.
Clin Cancer Res. 2003 Jul;9(7):2727-33. PMID: 12855653

Overexpression of kallikrein 10 in epithelial ovarian carcinomas.
Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R.
Gynecol Oncol. 2003 Jul;90(1):44-50. PMID: 12821340

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr.
J Biol Chem. 2003 Jun 27;278(26):23441-50. Epub 2003 Apr 16. PMID: 12700233

Status of tumor markers in ovarian cancer screening.
Bast RC Jr.
J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. Review. PMID: 12743135

Progress in the management of gynecologic cancer: consensus summary statement.
Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.
J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. PMID: 12743127

ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers.
Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC.
Oncogene. 2003 May 15;22(19):2897-909. PMID: 12771940

Epigenetic regulation of ARHI in breast and ovarian cancer cells.
Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Jr.
Ann N Y Acad Sci. 2003 Mar;983:268-77. Review. PMID: 12724231

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC.
Clin Cancer Res. 2003 Feb;9(2):845-52. PMID: 12576458

Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis.
Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC Jr.
Oncogene. 2003 Jan 30;22(4):484-97. PMID: 12555062

Prevention of ovarian cancer: intraepithelial neoplasia.
Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr.
Clin Cancer Res. 2003 Jan;9(1):20-30. Review. PMID: 12538447

Specific keynote: molecular therapeutics in ovarian cancer.
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J.
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. Review. PMID: 12586094

General keynote: molecular therapeutics and pharmacogenomics.
Bast RC Jr, Mills GB.
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S84-7; discussion S93-6. Review. PMID: 12586093

Specific keynote: chemoprevention of ovarian cancer: the journey begins.
Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC Jr, Brewer MA.
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S59-66; discussion S67-70. Review. PMID: 12586088

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE.
Gynecol Oncol. 2003 Jan;88(1):73-9. PMID: 12504632

Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC Jr.
Cancer Res. 2002 Dec 15;62(24):7264-72. PMID: 12499268

Heregulin-induced apoptosis.
Le XF, Varela CR, Bast RC Jr.
Apoptosis. 2002 Dec;7(6):483-91. Review. PMID: 12370490

Early detection of ovarian cancer: promise and reality.
Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G.
Cancer Treat Res. 2002;107:61-97. Review. PMID: 11775462

Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents.
Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast R.
J Biomed Opt. 2002 Jan;7(1):20-6. PMID: 11818008

Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC Jr.
Oncogene. 2001 Dec 13;20(57):8258-69. PMID: 11781840

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF.
Cancer. 2001 Dec 1;92(11):2837-44. PMID: 11753957

Translational research--traffic on the bridge.
Bast RC Jr, Mills GB, Young RC.
Biomed Pharmacother. 2001 Nov;55(9-10):565-71. Review. PMID: 11769968

Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics.
Mills GB, Bast RC Jr, Srivastava S.
J Natl Cancer Inst. 2001 Oct 3;93(19):1437-9. PMID: 11584052

High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC Jr, Gajewski JL, Champlin RE.
Gynecol Oncol. 2001 Sep;82(3):420-6. PMID: 11520135

Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention.
Brewer M, Utzinger U, Satterfield W, Hill L, Gershenson D, Bast R, Wharton JT, Richards-Kortum R, Follen M.
Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):889-93. PMID: 11489756

Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI.
Cancer Res. 2001 Aug 1;61(15):5895-904. PMID: 11479231

Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI.
Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RC Jr, Yu Y.
Biochim Biophys Acta. 2001 Jun 28;1519(3):216-22. PMID: 11418188

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel.
J Clin Oncol. 2001 Mar 15;19(6):1865-78. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185-8. J Clin Oncol 2002 Apr 15;20(8):2213. PMID: 11251019

Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.
Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr, Stack MS.
Gynecol Oncol. 2001 Feb;80(2):245-53. PMID: 11161867

Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC Jr.
Gynecol Oncol. 2001 Feb;80(2):145-55. PMID: 11161852

Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL 3rd, Willey J, Bast R, Hortobagyi GN.
Cancer Invest. 2001;19(5):459-66. PMID: 11458813

Fluorescence spectroscopy for in vivo characterization of ovarian tissue.
Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC Jr, Follen M, Richards-Kortum R.
Lasers Surg Med. 2001;29(2):128-35. PMID: 11553899

Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers.
Bast RC Jr, Mills GB.
Methods Mol Med. 2001;39:37-48. PMID: 21340756

Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer.
Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC Jr.
Oncogene. 2000 Dec 14;19(54):6277-85. PMID: 11175342

Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells.
Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr, Mills GB.
Biochem J. 2000 Dec 1;352 Pt 2:475-82. PMID: 11085941

Long-term follow-up of the Stockholm screening study on ovarian cancer.
Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V Jr, Sjövall K.
Gynecol Oncol. 2000 Dec;79(3):466-70. PMID: 11104621

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ.
Int J Cancer. 2000 Nov 20;89(6):519-23. PMID: 11102897

Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.
Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC Jr, Mills GB.
Biochem J. 2000 Nov 15;352 Pt 1:135-43. PMID: 11062066

Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.
Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB.
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11960-5. PMID: 11035810

The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice.
Xu F, Xia W, Luo RZ, Peng H, Zhao S, Dai J, Long Y, Zou L, Le W, Liu J, Parlow AF, Hung MC, Bast RC Jr, Yu Y.
Cancer Res. 2000 Sep 1;60(17):4913-20. PMID: 10987306

Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC Jr.
Clin Cancer Res. 2000 Aug;6(8):3334-41. PMID: 10955821

Differential signaling by an anti-p185(HER2) antibody and heregulin.
Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC Jr.
Cancer Res. 2000 Jul 1;60(13):3522-31. PMID: 10910064

High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE.
Bone Marrow Transplant. 2000 Jun;25(11):1137-40. PMID: 10849525

ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC Jr, Yu Y.
Int J Cancer. 2000 Jun 1;86(5):690-4. PMID: 10797292

Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC Jr.
Clin Cancer Res. 2000 Jan;6(1):260-70. PMID: 10656457

Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.
Bösze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Vermorken JB, Wells M, Wilbanks GD.
Eur J Gynaecol Oncol. 2000;21(5):513-26. Review. PMID: 11198047

Molecular approaches to management of epithelial ovarian cancer.
Bast RC, Yu Y, Xu FJ, Le XF, Mills GB.
Int J Gynecol Cancer. 2000 Jan;10(S1):2-7. PMID: 11240724

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.
Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB.
Clin Cancer Res. 1999 Dec;5(12):4308-18. PMID: 10632375

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC Jr, Mills GB, Silva EG.
Clin Cancer Res. 1999 Dec;5(12):4053-8. PMID: 10632339

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.
Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB.
Oncogene. 1999 Nov 18;18(48):6635-40. PMID: 10597268

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC Jr, Mills GB.
Clin Cancer Res. 1999 Nov;5(11):3704-10. PMID: 10589790

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr.
Clin Cancer Res. 1999 Nov;5(11):3653-60. PMID: 10589783

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, Gershenson DM.
Gynecol Oncol. 1999 Nov;75(2):261-6. PMID: 10525383

Ovarian cancer identified through screening with serum markers but not by pelvic imaging.
Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs IJ.
Int J Gynecol Cancer. 1999 Nov;9(6):497-501. PMID: 11240818

Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL 3rd, Bast R, Hortobagyi GN.
Cancer. 1999 Oct 1;86(7):1251-7. PMID: 10506711

Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, Affleck DJ, Bast RC Jr.
Nucl Med Biol. 1999 Oct;26(7):781-90. PMID: 10628557

Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness.
Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC Jr, Goldstein MG, Novack D, Lenzi R.
Cancer. 1999 Sep 1;86(5):887-97. PMID: 10463990

Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?
Mills GB, Schmandt R, Gershenson D, Bast RC.
Clin Cancer Res. 1999 Sep;5(9):2286-8. PMID: 10499594

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr.
Int J Cancer. 1999 Aug 12;82(4):525-31. PMID: 10404066

Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick GE.
Clin Cancer Res. 1999 Aug;5(8):2164-70. Erratum in: Clin Cancer Res 1999 Oct;5(10):2980. PMID: 10473101

OVX1 radioimmunoassay results are dependent on the method of sample collection and storage.
Hogdall EV, Hogdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ.
Clin Chem. 1999 May;45(5):692-4. PMID: 10222361

Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC Jr.
Gynecol Oncol. 1999 Apr;73(1):56-61. PMID: 10094881

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH.
Clin Cancer Res. 1999 Mar;5(3):655-63. PMID: 10100719

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr.
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. PMID: 9874798

Prevention of ovarian cancer.
Brewer MA, Mitchell MF, Bast RC.
In Vivo. 1999 Jan-Feb;13(1):99-106. Review. PMID: 10218141

Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean G, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC Jr.
Clin Cancer Res. 1998 Oct;4(10):2545-50. PMID: 9796989

CA 125: the past and the future.
Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB.
Int J Biol Markers. 1998 Oct-Dec;13(4):179-87. Review. PMID: 10228898

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT.
Gynecol Oncol. 1998 Sep;70(3):404-9. PMID: 9790795

Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
Bast RC Jr, Pusztai L, Kerns B, MacDonald J, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A.
Hybridoma. 1998 Aug;17(4):313-21. PMID: 9790065

CA 125 in ovarian cancer: advances and controversy.
Fritsche HA, Bast RC.
Clin Chem. 1998 Jul;44(7):1379-80. PMID: 9665412

Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC Jr.
Gynecol Oncol. 1998 Jul;70(1):49-55. PMID: 9698473

OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
Martell RE, Xu FJ, Davis WZ, Anselmino L, Yu YH, Daly L, Bast RC Jr.
Int J Biol Markers. 1998 Jul-Sep;13(3):145-9. PMID: 10079388

Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.
Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC Jr, Ostrowski MC.
Cancer Res. 1998 May 15;58(10):2253-9. PMID: 9605774

Expression of p16 induces transcriptional downregulation of the RB gene.
Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC Jr, Mills GB.
Oncogene. 1998 Jan 8;16(1):1-8. PMID: 9467937

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.
Pusztai L, Siddik ZH, Mills GB, Bast RC Jr.
Acta Oncol. 1998;37(7-8):629-40. Review. PMID: 10050979

SCC antigen. Summary remarks.
Bast RC.
Tumour Biol. 1998;19(6):527-8. PMID: 9817982

Summary of the first Emil J Freireich symposium.
Bast RC Jr.
Clin Cancer Res. 1997 Dec;3(12 Pt 2):2708-10. Review. PMID: 10068278

Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition.
Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX.
Oncogene. 1997 Nov 20;15(21):2589-96. PMID: 9399646

Improving physician-patient communication in cancer care: outcome of a workshop for oncologists.
Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC Jr.
J Cancer Educ. 1997 Fall;12(3):166-73. PMID: 9376255

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr.
Clin Cancer Res. 1997 Sep;3(9):1629-34. PMID: 9815853

Radioiodinated antibody targeting of the HER-2/neu oncoprotein.
Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC Jr, Zalutsky MR.
Nucl Med Biol. 1997 Jul;24(5):451-9. PMID: 9290082

The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC Jr.
Biol Blood Marrow Transplant. 1997 Jun;3(2):91-7. PMID: 9267669
 
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity.
Fang X, Gibson S, Flowers M, Furui T, Bast RC Jr, Mills GB.
J Biol Chem. 1997 May 23;272(21):13683-9. PMID: 9153219

Is OVX1 a suitable marker for endometrial cancer?
Beck EP, Wagner M, Anselmino L, Xu F, Bast RC Jr, Jaeger W.
Gynecol Oncol. 1997 May;65(2):291-6. PMID: 9159340

Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma.
van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V.
Hum Pathol. 1996 Nov;27(11):1185-91. PMID: 8912829
 
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ.
J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66. Review. PMID: 8841020
 
Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.
Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS.
Gynecol Oncol. 1996 Jul;62(1):89-99. PMID: 8690299
 
Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC Jr, Hacker NF.
Cancer. 1996 May 15;77(10):2092-8. PMID: 8640675
 
Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression.
Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC Jr.
Gynecol Oncol. 1996 May;61(2):233-40. PMID: 8626139
 
Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin.
Skubitz AP, Bast RC Jr, Wayner EA, Letourneau PC, Wilke MS.
Am J Pathol. 1996 May;148(5):1445-61. PMID: 8623916
 
Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC Jr.
Am J Obstet Gynecol. 1996 Apr;174(4):1316-9. PMID: 8623863
 
A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow.
Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, Layfield L, Peters WP, Bast RC Jr.
J Hematother. 1996 Feb;5(1):57-62. PMID: 8646482
 
Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique.
Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC Jr.
Clin Cancer Res. 1996 Jan;2(1):81-6. PMID: 9816094
 
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop.
Nap M, Vitali A, Nustad K, Bast RC Jr, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J.
Tumour Biol. 1996;17(6):325-31. PMID: 8938947
 
Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support.
Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB.
Breast Cancer Res Treat. 1996;41(1):1-13. PMID: 8932871
 
Molecular genetic features of ovarian cancer.
Berchuck A, Kohler MF, Bast RC Jr.
Prog Clin Biol Res. 1996;394:269-84. Review. PMID: 8778801
 
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine.
Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J.
Tumour Biol. 1996;17(4):196-219. PMID: 8685601
 
Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
Vredenburgh JJ, Peters WP, Rosner G, DeSombre K, Johnston WW, Kamel A, Wu K, Bast RC Jr.
Bone Marrow Transplant. 1995 Dec;16(6):815-21. PMID: 8750275
 
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS, Bast RC Jr.
Cancer. 1995 Nov 15;76(10 Suppl):2092-6. Review. PMID: 8635006
 
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.
Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, Bast RC Jr, Knapp RC.
Cancer. 1995 Nov 15;76(10 Suppl):2004-10. PMID: 8634992
 
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB.
Cancer. 1995 Nov 1;76(9):1615-20. PMID: 8635066
 
p53-based gene therapy of ovarian cancer: magic bullet?
Berchuck A, Bast RC Jr.
Gynecol Oncol. 1995 Nov;59(2):169-70. PMID: 7590466
 
Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130.
Xu F, Yu Y, Bast RC Jr, Cornélissen G, Fujii S, Takagi M, O'Brien T, Halberg F.
In Vivo. 1995 Jul-Aug;9(4):407-12. PMID: 8555442
 
Spectral differences between epitopes in the cronomes of salivary CA130 and CA125.
Portela A, Cornélissen G, Halberg F, Bast RC Jr, Fujii S, Xu F, Yu Y, Takagi M, Halberg J, Halberg F, Berg H, O'Brien T, Walker R, Haus E, Illera JC, Illera M.
In Vivo. 1995 Jul-Aug;9(4):341-6. PMID: 8555433
 
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr, Berchuck A.
Cancer Res. 1995 Feb 15;55(4):944-8. PMID: 7531618
 
Molecular approaches to prevention and detection of epithelial ovarian cancer.
Bast RC Jr, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A.
J Cell Biochem Suppl. 1995;23:219-22. Review. PMID: 8747399

Clinical and laboratory directions for ovarian cancer research.
Bast RC Jr.
Gynecol Oncol. 1994 Dec;55(3 Pt 2):S164-7. Review. PMID: 7835802
 
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, Marks JR.
Cell Growth Differ. 1994 Dec;5(12):1301-7. PMID: 7696178
 
The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC Jr.
Int J Cancer. 1994 Oct 15;59(2):242-7. PMID: 7927925
 
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.
McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekut L, Truesdale A, Vereghese M, Warner J, Ways JP.
Nature. 1994 Aug 18;370(6490):558-61. PMID: 8052311
 
Pathogenesis of ovarian cancers.
Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr.
J Soc Gynecol Investig. 1994 Jul-Sep;1(3):181-90. PMID: 9419769
 
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A.
Cancer. 1994 Jul 1;74(1):93-9. PMID: 8004589
 
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC Jr, McCulloch W.
Blood. 1994 Jun 1;83(11):3132-7. PMID: 8193351
 
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Young TN, Rodriguez GC, Moser TL, Bast RC Jr, Pizzo SV, Stack MS.
Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1285-96. PMID: 8178854
 
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC Jr, Berchuck A.
Cancer. 1994 May 1;73(9):2380-5. PMID: 7909491
 
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.
Wu S, Meeker WA, Wiener JR, Berchuck A, Bast RC Jr, Boyer CM.
Gynecol Oncol. 1994 Apr;53(1):59-63. PMID: 8175024
 
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC Jr.
Am J Obstet Gynecol. 1994 Apr;170(4):1177-83. PMID: 8166206
 
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1.
Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC Jr, Solomon E.
Hum Mol Genet. 1994 Apr;3(4):589-94. PMID: 8069304
 
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC Jr.
J Natl Cancer Inst. 1994 Mar 2;86(5):372-8. PMID: 7905928
 
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC Jr, Stack MS.
Int J Cancer. 1994 Feb 15;56(4):552-9. PMID: 8112891
 
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC Jr, Layfield LJ.
Am J Clin Pathol. 1994 Feb;101(2):192-7. PMID: 8116574
 
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC.
Gynecol Oncol. 1994 Feb;52(2):232-6. PMID: 7508877
 
The p53 tumor suppressor gene frequently is altered in gynecologic cancers.
Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr.
Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246-52. Review. PMID: 8296829
 
Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS, Kohler MF, Marks JR, Bast RC Jr, Boyd J, Berchuck A.
Obstet Gynecol. 1994 Jan;83(1):118-24. PMID: 8272291

Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
Bast RC Jr, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM.
Immunol Ser. 1994;61:23-30. Review. PMID: 7912111
 
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.
van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V.
Eur J Cancer. 1994;30A(8):1096-9. PMID: 7654437
 
Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.
Jacobs IJ, Rivera H, Oram DH, Bast RC Jr.
Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4. PMID: 8297846
 
Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr.
J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51. PMID: 8411259
 
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.
Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC Jr.
J Clin Invest. 1993 Nov;92(5):2440-7. PMID: 8227359

Perspectives on the future of cancer markers.
Bast RC Jr.
Clin Chem. 1993 Nov;39(11 Pt 2):2444-51. Review. PMID: 8222257
 
Progress in radioimmunotherapy.
Bast RC Jr.
N Engl J Med. 1993 Oct 21;329(17):1266-8. PMID: 8413396
 
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, Berchuck A.
J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9. PMID: 8360934
 
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.
Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A.
Am J Obstet Gynecol. 1993 Sep;169(3):690-4. PMID: 8372881
 
The biology of ovarian cancer.
Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr, Berchuck A.
Curr Opin Oncol. 1993 Sep;5(5):900-7. Review. PMID: 8218503
 
National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer.
Gallion HH, Bast RC Jr.
Cancer Res. 1993 Aug 15;53(16):3839-42. PMID: 8339296
 
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.
Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC Jr.
Exp Cell Res. 1993 Aug;207(2):332-9. PMID: 8344385
 
Screening for ovarian cancer. Multiple markers may outperform CA 125 alone.
Bast R, Woolas R.
BMJ. 1993 Jun 19;306(6893):1684-5. PMID: 8324445
 
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr.
Cancer. 1993 Jun 15;71(12):3942-6. PMID: 8099528
 
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E.
J Clin Oncol. 1993 Jun;11(6):1132-43. PMID: 8501500
 
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.
Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC Jr, Kinney RB, Berchuck A.
Am J Clin Pathol. 1993 Jun;99(6):736-40. PMID: 8322710
 
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A.
Obstet Gynecol. 1993 May;81(5 ( Pt 1)):643-50. PMID: 8469448
 
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC Jr.
Cancer Res. 1993 Apr 15;53(8):1939-44. PMID: 8385577
 
Cell growth regulation in epithelial ovarian cancer.
Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A.
Cancer. 1993 Feb 15;71(4 Suppl):1597-601. Review. PMID: 8431895
 
Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr.
Int J Cancer. 1993 Feb 1;53(3):401-8. PMID: 7679090
 
Growth regulation and transformation of ovarian epithelium.
Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Jr.
Cancer. 1993 Jan 15;71(2 Suppl):545-51. Review. PMID: 8420675
 
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC Jr.
Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):228-32. PMID: 8420332

Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr.
J Natl Cancer Inst. 1992 Dec 2;84(23):1793-8. PMID: 1433368
 
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.
Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1992 Dec;167(6):1877-82. PMID: 1361720
 
Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr.
Cancer. 1992 Oct 15;70(8):2137-42. PMID: 1394043
 
Biology and therapy with biologic agents in gynecologic cancer.
Wiener JR, Berchuck A, Bast RC Jr.
Curr Opin Oncol. 1992 Oct;4(5):946-54. Review. PMID: 1457511
 
Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ, Oram DH, Bast RC Jr.
Obstet Gynecol. 1992 Sep;80(3 Pt 1):396-9. PMID: 1495694
 
Oncogenes in ovarian cancer.
Berchuck A, Kohler MF, Bast RC Jr.
Hematol Oncol Clin North Am. 1992 Aug;6(4):813-27. Review. PMID: 1500387
 
Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L, Ferguson J, Cram GP Jr, Hars V, George SL, McCarty KS Jr, Bast RC Jr.
J Clin Oncol. 1992 Jul;10(7):1057-65. PMID: 1607912
 
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC Jr, Iglehart JD, Marks JR.
J Histochem Cytochem. 1992 Jul;40(7):1047-51. PMID: 1607637
 
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr.
Obstet Gynecol. 1992 Jul;80(1):14-8. PMID: 1603484
 
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy.
Cornélissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ 3rd, Halberg F, Tamura K.
Chronobiologia. 1992 Jul-Dec;19(3-4):131-49. PMID: 1362146
 
Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody.
Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC Jr.
Cancer. 1992 Jun 15;69(12):2894-904. PMID: 1375528
 
Malignant transformation of ovarian epithelium.
Bast RC Jr, Jacobs I, Berchuck A.
J Natl Cancer Inst. 1992 Apr 15;84(8):556-8. PMID: 1556762
 
Overexpression and mutation of p53 in endometrial carcinoma.
Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR.
Cancer Res. 1992 Mar 15;52(6):1622-7. PMID: 1540970
 
Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.
Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr.
Am J Obstet Gynecol. 1992 Mar;166(3):997-1007. PMID: 1550178
 
The use of tumor markers in the management of patients with gynecologic carcinomas.
Berchuck A, Boente MP, Bast RC Jr.
Clin Obstet Gynecol. 1992 Mar;35(1):45-54. Review. PMID: 1544249
 
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1992 Feb;166(2):676-84. PMID: 1536252
 
Ploidy analysis of epithelial ovarian cancers using image cytometry.
Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC Jr, Bacus SS.
Gynecol Oncol. 1992 Jan;44(1):61-5. PMID: 1370427

Detection of minimal residual breast cancer in bone marrow.
Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC, Ceriani RL, Franklin W.
Prog Clin Biol Res. 1992;377:637-42. PMID: 1438446
 
Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer.
Lidor YJ, Shpall EJ, Peters WP, Bast RC Jr.
Int J Cancer. 1991 Nov 11;49(5):704-10. PMID: 1937956
 
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC Jr.
Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62. PMID: 1957862
 
Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC, Zurawski VR Jr, Schlom J, Kufe DW, Ritts RE Jr.
Cancer. 1991 Oct 15;68(8):1758-63. PMID: 1913520
 
Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out.
Bast RC Jr, Capizzi RL, Pagano JS, Wiley AL Jr.
N C Med J. 1991 Oct;52(10):496-8. PMID: 1944619
 
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC Jr.
Cancer Res. 1991 Oct 1;51(19):5361-9. PMID: 1680547
 
Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC Jr.
Cancer. 1991 Sep 15;68(6):1272-8. PMID: 1873781
 
The immunobiology and immunotherapy of ovarian cancer.
Bookman MA, Bast RC Jr.
Semin Oncol. 1991 Jun;18(3):270-91. Review. PMID: 1710393
 
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ.
Cancer Res. 1991 Jun 1;51(11):2908-16. PMID: 1709586
 
Summary of symposium: Biology and therapy of ovarian cancer.
Ozols RF, Hamilton TC, Hoskins WJ, Bast RC Jr, Young RC.
Semin Oncol. 1991 Jun;18(3):297-306. PMID: 2042066
 
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A.
Cancer Res. 1991 Jun 1;51(11):2979-84. PMID: 2032235
 
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.
Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1991 Mar;164(3):745-50. PMID: 2003535
 
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1991 Feb;164(2):669-74. PMID: 1992720
 
Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation.
Shpall EJ, Bast RC Jr, Joines WT, Jones RB, Anderson I, Johnston C, Eggleston S, Tepperberg M, Edwards S, Peters WP.
Bone Marrow Transplant. 1991 Feb;7(2):145-51. PMID: 2049558
 
Coexpression of different antigenic markers on moieties that bear CA 125 determinants.
Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT, Klug TL, Zurawski VR Jr, Bast RC Jr.
Cancer Res. 1991 Jan 15;51(2):468-75. PMID: 1702359
 
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Shpall EJ, Jones RB, Bast RC Jr, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M.
J Clin Oncol. 1991 Jan;9(1):85-93. PMID: 1985173
 
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21. PMID: 1670908

Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms.
Harłozińska A, Bar JK, Rabczyński J, Bast RC, Richter R, Cisło M.
Tumori. 1990 Oct 31;76(5):505-10. PMID: 1701581
 
Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1204-9. PMID: 2220931
 
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr.
Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164-7. PMID: 2171337
 
Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.
Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr.
Obstet Gynecol. 1990 Sep;76(3 Pt 1):381-7. PMID: 1974342
 
The role of tumor markers in gynecologic oncology.
Olt G, Berchuck A, Bast RC Jr.
Obstet Gynecol Surv. 1990 Sep;45(9):570-7. Review. PMID: 1697940
 
CA 125 levels in menopausal women.
Westhoff C, Gollub E, Patel J, Rivera H, Bast R Jr.
Obstet Gynecol. 1990 Sep;76(3 Pt 1):428-31. PMID: 2381621
 
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC Jr, Ross M, Lidor Y, Vanacek K, Tyler T.
Gynecol Oncol. 1990 Sep;38(3):386-91. PMID: 2121627
 
Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology.
Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC Jr.
Am J Clin Pathol. 1990 Jul;94(1):8-13. PMID: 2193508
 
Antigenic heterogeneity in human ovarian cancer.
Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC Jr.
Gynecol Oncol. 1990 Jul;38(1):12-6. PMID: 2162315
 
Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC Jr.
Am J Obstet Gynecol. 1990 Apr;162(4):883-8. PMID: 2327461
 
Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer.
Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, Eklund G, Mattsson B, Connor RJ, Prorok PC, Knapp RC, Einhorn N.
Gynecol Oncol. 1990 Mar;36(3):299-305. PMID: 2318438
 
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr.
Gynecol Oncol. 1990 Feb;36(2):161-5. PMID: 2404835
 
The role of peptide growth factors in epithelial ovarian cancer.
Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC Jr, Boyer CM.
Obstet Gynecol. 1990 Feb;75(2):255-62. PMID: 2300354
 
Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC Jr.
Obstet Gynecol. 1990 Feb;75(2):249-54. PMID: 2300353
 
Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation.
Shpall EJ, Anderson IC, Bast RC Jr, Joines WT, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M, Affronti ML, Coniglio D, Mathias B, Peters WP.
Prog Clin Biol Res. 1990;333:321-35; discussion 336. PMID: 2308989
 
Gynecologic tumor markers.
Olt GJ, Berchuck A, Bast RC Jr.
Semin Surg Oncol. 1990;6(6):305-13. Review. PMID: 2263805

Immunodiagnosis of ovarian tumors.
Jacobs I, Bast RC Jr.
Immunol Ser. 1990;53:323-38. Review. PMID: 2100566

Autologous bone marrow transplantation for acute lymphoblastic leukemia.
Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC Jr.
J Clin Oncol. 1989 Nov;7(11):1594-601. PMID: 2809677
 
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.
Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS Jr, Bast RC Jr.
Am J Obstet Gynecol. 1989 Nov;161(5):1258-63. PMID: 2589448
 
Epidermal growth factor receptor expression in normal and malignant endometrium.
Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC Jr, McCarty KS Jr.
Am J Obstet Gynecol. 1989 Nov;161(5):1247-52. PMID: 2480065
 
Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues.
Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Bast RC Jr, McCarty KS Jr.
Arch Pathol Lab Med. 1989 Oct;113(10):1155-8. PMID: 2802945
 
Elimination of malignant clonogenic breast cancer cells from human bone marrow.
Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC Jr.
Cancer Res. 1989 Aug 15;49(16):4659-64. PMID: 2663144
 
Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines.
Boyer CM, Dawson DV, Neal SE, Winchell LF, Leslie DS, Ring D, Bast RC Jr.
Cancer Res. 1989 Jun 1;49(11):2928-34. PMID: 2497969
 
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.
Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB, McCarty KS Jr, Bast RC Jr.
Cancer Res. 1989 Apr 15;49(8):2091-5. PMID: 2702650
 
Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines.
Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, Brown EL.
J Clin Invest. 1989 Mar;83(3):921-6. PMID: 2646321
 
CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation.
Ciobanu N, Runowicz CD, Wiernik PH, Strauman T, Sheridan C, Bast RC Jr.
Am J Obstet Gynecol. 1989 Feb;160(2):354-5. PMID: 2644834
 
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells.
Boyer CM, Borowitz MJ, McCarty KS Jr, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC Jr.
Int J Cancer. 1989 Jan 15;43(1):55-60. PMID: 2463226
 
Antigens associated with epithelial ovarian carcinomas.
Bast RC Jr.
Prog Clin Biol Res. 1989;288:73-83. PMID: 2785696
 
Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.
Zalutsky MR, Bast RC Jr, Knapp RC.
Int J Rad Appl Instrum B. 1989;16(4):405-11. PMID: 2777582
 
CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary.
Einhorn N, Knapp RC, Bast RC, Zurawski VR Jr.
Acta Oncol. 1989;28(5):655-7. PMID: 2590540
 
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC Jr, Moore JO.
Cancer Chemother Pharmacol. 1989;23(6):377-83. PMID: 2653660
 
The CA 125 tumour-associated antigen: a review of the literature.
Jacobs I, Bast RC Jr.
Hum Reprod. 1989 Jan;4(1):1-12. Review. PMID: 2651469

Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.
Conkling PR, Chua CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC Jr, Weinberg JB.
Cancer Res. 1988 Oct 1;48(19):5604-9. PMID: 3046744
 
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO.
J Clin Oncol. 1988 Sep;6(9):1368-76. PMID: 3047332
 
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease.
Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE.
Am J Obstet Gynecol. 1988 Aug;159(2):341-6. PMID: 2457318
 
Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support.
Olsen GA, Gockerman JP, Bast RC Jr, Borowitz M, Peters WP.
Transplantation. 1988 Jul;46(1):57-60. PMID: 3293287
 
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.
Zurawski VR Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC Jr, Ritts RE Jr, Malkasian G.
Gynecol Oncol. 1988 May;30(1):7-14. PMID: 2452773
 
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC Jr, Gilbert CJ, Oette DH.
N Engl J Med. 1988 Apr 7;318(14):869-76. PMID: 3281007
 
Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
Knauf S, Bast RC Jr.
Int J Biol Markers. 1988 Apr-Jun;3(2):75-81. PMID: 3243980
 
Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.
Zalutsky MR, Knapp RC, Bast RC Jr.
Int J Rad Appl Instrum B. 1988;15(4):431-7. PMID: 3255739
 
Serotherapy of ovarian cancer.
Lidor Y, Bast RC Jr.
Nat Immun Cell Growth Regul. 1988;7(4):193-215. Review. PMID: 3070370
 
The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide.
Koerner TJ, Hamilton TA, Introna M, Tannenbaum CS, Bast RC Jr, Adams DO.
Biochem Biophys Res Commun. 1987 Dec 31;149(3):969-74. PMID: 3426621
 
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.
Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC Jr, Seigler HF, Colvin OM.
Cancer Res. 1987 Dec 1;47(23):6402-6. PMID: 2824032
 
Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer.
Leoni F, Bast RC Jr, Canevari S, Menard S, Soper JT, Colnaghi MI.
Int J Cancer. 1987 Nov 15;40(5):592-7. PMID: 2445699

Pros and cons of gynecologic tumor markers.
Bast RC Jr, Hunter V, Knapp RC.
Cancer. 1987 Oct 15;60(8 Suppl):1984-92. Review. PMID: 2443235
 
Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Haleem A, Kurtzberg J, Olsen GA, Rhinehardt-Clark A, Leslie DS, Ray L, Smith CA, Peters WP, Haynes BF, Bast RC Jr.
Cancer Res. 1987 Sep 1;47(17):4608-12. PMID: 3113721
 
The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages.
Introna M, Bast RC Jr, Tannenbaum CS, Hamilton TA, Adams DO.
J Immunol. 1987 Jun 1;138(11):3891-6. PMID: 3108379
 
Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages.
Introna M, Bast RC Jr, Johnston PA, Adams DO, Hamilton TA.
J Cell Physiol. 1987 Apr;131(1):36-42. PMID: 3571335
 
Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
Zurawski VR Jr, Broderick SF, Pickens P, Knapp RC, Bast RC Jr.
Obstet Gynecol. 1987 Apr;69(4):606-11. PMID: 2434895
 
CA 125 for the monitoring of ovarian carcinoma during primary therapy.
Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC Jr.
Obstet Gynecol. 1987 Feb;69(2):223-7. PMID: 2433652
 
Co-expression of human cancer-associated epitopes on mucin molecules.
Lan MS, Bast RC Jr, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS.
Int J Cancer. 1987 Jan 15;39(1):68-72. PMID: 2432019
 
The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma.
Bast RC Jr, Knapp RC.
Important Adv Oncol. 1987:39-53. Review. PMID: 3331386

Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.
Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL.
Cancer Res. 1986 Dec;46(12 Pt 1):6143-8. PMID: 2430690
 
Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes.
Introna M, Hamilton TA, Kaufman RE, Adams DO, Bast RC Jr.
J Immunol. 1986 Oct 15;137(8):2711-5. PMID: 3760571
 
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy.
Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E 3rd, Schnipper LE.
Cancer Res. 1986 Sep;46(9):4496-9. PMID: 3524814
 
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.
Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR Jr, Bast RC Jr.
Am J Obstet Gynecol. 1986 Jul;155(1):56-60. PMID: 3460341
 
Elevated serum concentrations of CA-125 in patients with advanced endometriosis.
Barbieri RL, Niloff JM, Bast RC Jr, Scaetzl E, Kistner RW, Knapp RC.
Fertil Steril. 1986 May;45(5):630-4. PMID: 3457709
 
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, Anderson J, Anderson K, Kruskoff MS, Schnipper L, Frei E III.
J Clin Oncol. 1986 May;4(5):646-54. PMID: 3517240
 
CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC Jr.
Obstet Gynecol. 1986 May;67(5):685-9. PMID: 3457330
 
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M, De Fabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC Jr.
Cancer Res. 1986 Mar;46(3):1208-13. PMID: 3510720
 
Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr.
Obstet Gynecol. 1986 Mar;67(3):414-6. PMID: 2418395
 
Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement.
De Fabritiis P, Bregni M, Lipton J, Reynolds C, Nadler L, Ritz J, Bast RC Jr.
Leuk Res. 1986;10(1):35-42. PMID: 2935682
 
Long-term culture of human granulocytes and granulocyte progenitor cells.
Greenberger JS, FitzGerald TJ, Rothstein L, Pierce J, Sakakeeny MA, Weichselbaum RR, Naparstek E, Newburger P, Griffin J, Bast R Jr, Key L, Daugherty C.
Prog Clin Biol Res. 1986;211:159-85. Review. PMID: 3008194
 
Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody.
Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS.
Ann Surg. 1985 Oct;202(4):440-5. PMID: 4051597
 
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW.
J Clin Oncol. 1985 Oct;3(10):1355-63. PMID: 2413181
 
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma.
Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ, Knapp RC.
Gynecol Oncol. 1985 Sep;22(1):115-20. PMID: 2410329
 
A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients.
Knauf S, Anderson DJ, Knapp RC, Bast RC Jr.
Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 1):911-3. PMID: 2411137
 
Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
Niloff JM, Knapp RC, Jones G, Schaetzl EM, Bast RC Jr.
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):895-6. PMID: 4016797
 
Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma.
Bast RC Jr, Knapp RC.
Eur J Obstet Gynecol Reprod Biol. 1985 Jun;19(6):354-6. PMID: 4018373
 
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC Jr.
Blood. 1985 May;65(5):1064-70. PMID: 3995166
 
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.
Niloff JM, Bast RC Jr, Schaetzl EM, Knapp RC.
Am J Obstet Gynecol. 1985 Apr 1;151(7):981-6. PMID: 3157319
 
Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast R Jr, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA.
Cancer Res. 1985 Feb;45(2):758-67. PMID: 3967246
 
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Bast RC Jr, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J.
Cancer Res. 1985 Feb;45(2):499-503. PMID: 3967224
 
Chemotactic anti-tumor antibodies: in vitro results with four different antibody preparations.
Obrist R, Obrecht JP, Bast RC Jr, Sandberg AL.
Adv Exp Med Biol. 1985;186:827-32. PMID: 4050600

Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
Berek JS, Bast RC Jr, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J.
Obstet Gynecol. 1984 Nov;64(5):708-14. PMID: 6493663
 
CA125 antigen levels in obstetric and gynecologic patients.
Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr.
Obstet Gynecol. 1984 Nov;64(5):703-7. PMID: 6208522
 
Immunologic approaches to the management of ovarian carcinoma.
Bast RC Jr, Knapp RC.
Semin Oncol. 1984 Sep;11(3):264-74. Review. PMID: 6207593
 
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma.
Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF.
Lancet. 1984 Aug 25;2(8400):427-31. PMID: 6147502
 
Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A, Berek J, Bast R, Spina C, Hacker N, Knapp RC, Zighelboim J.
J Biol Response Mod. 1984 Aug;3(4):371-8. PMID: 6541243
 
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR Jr, Knapp RC.
Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9. PMID: 6204531
 
Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.
Masuho Y, Zalutsky M, Knapp RC, Bast RC Jr.
Cancer Res. 1984 Jul;44(7):2813-9. PMID: 6202400
 
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix.
Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr.
Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8. PMID: 6201072
 
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas.
Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr.
Cancer Res. 1984 Mar;44(3):1048-53. PMID: 6198078
 
Somatic activation of rasK gene in a human ovarian carcinoma.
Feig LA, Bast RC Jr, Knapp RC, Cooper GM.
Science. 1984 Feb 17;223(4637):698-701. PMID: 6695178
 
Clinical applications of monoclonal antibodies in acute leukemia.
Ritz J, Bast RC Jr, Takvorian T, Sallan SE.
Ann N Y Acad Sci. 1984;428:308-17. PMID: 6234835
 
Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms.
Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK.
Int J Cancer. 1983 Nov 15;32(5):547-54. PMID: 6358053
 
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC.
N Engl J Med. 1983 Oct 13;309(15):883-7. PMID: 6310399
 
Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.
Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast RC Jr.
Am J Obstet Gynecol. 1983 Jul 15;146(6):607-12. PMID: 6346879
 
Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes.
Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF.
Clin Immunol Immunopathol. 1983 Jul;28(1):101-14. PMID: 6409485

Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC Jr, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC.
Cancer Res. 1983 Mar;43(3):1395-401. PMID: 6825108
 
Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
Bast RC Jr, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG, Schlossman SF.
Cancer Res. 1983 Mar;43(3):1389-94. PMID: 6337707
 
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.
Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB.
Am J Clin Pathol. 1983 Jan;79(1):98-104. PMID: 6336888
 
Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate.
Valone FH, Obrist R, Tarlin N, Bast RC Jr.
Cancer Res. 1983 Jan;43(1):197-201. PMID: 6401164
 
In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia.
Ritz J, Sallan SE, Bast RC Jr, Lipton JM, Nathan DG, Schlossman SF.
Haematol Blood Transfus. 1983;28:117-23. PMID: 6345287
 
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.
Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB.
Int J Gynecol Pathol. 1983;2(3):275-85. PMID: 6196309
 
Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma.
Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC Jr.
Int J Immunopharmacol. 1983;5(4):307-14. PMID: 6629591

Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature.
Galli SJ, Bast RC Jr, Bast BS, Isomura T, Zbar B, Rapp HJ, Dvorak HF.
J Immunol. 1982 Aug;129(2):890-9. PMID: 6282973
 
Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement.
Ritz J, Sallan SE, Bast RC Jr, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF.
Lancet. 1982 Jul 10;2(8289):60-3. PMID: 6177990
 
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC.
J Clin Invest. 1981 Nov;68(5):1331-7. PMID: 7028788
 
Elimination of leukemic cells from rat bone marrow using antibody and complement.
Feeney M, Knapp RC, Greenberger JS, Bast RC Jr.
Cancer Res. 1981 Sep;41(9 Pt 1):3331-5. PMID: 6942913
 
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Clavell LA, Lipton JM, Bast RC Jr, Kudisch M, Pesando J, Scholssman SF, Ritz J.
Blood. 1981 Aug;58(2):333-6. PMID: 6941821
 
Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue.
Bast RC Jr, Miller H, Rapp HJ, Gelboin HV.
J Natl Cancer Inst. 1981 Aug;67(2):359-64. PMID: 6943374
 
HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands.
Berkowitz RS, Hornig-Rohan J, Martin-Alosco S, Klein S, Goldstein DP, Bast RC Jr, DeWolf WC.
Placenta Suppl. 1981;3:263-7. PMID: 6963960
 
Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guérin and tumor cells.
Zbar B, Canti G, Rapp HJ, Ashley MP, Sukumar S, Bast RC Jr.
Cancer Res. 1980 Apr;40(4):1036-42. PMID: 7357533
 
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
Frei E 3rd, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP.
Am J Med. 1980 Mar;68(3):370-6. PMID: 6965819
 
Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells.
Bast RC Jr, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF.
J Natl Cancer Inst. 1980 Feb;64(2):365-72. PMID: 6986493
 
Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC Jr, Knapp RC, Mitchell AK, Thurston JG, Tucker RW, Schlossman SF.
J Immunol. 1979 Nov;123(5):1945-51. PMID: 489967
 
Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins.
Okuda T, Vesell ES, Plotkin E, Tarone R, Bast RC, Gelboin HV.
Cancer Res. 1977 Nov;37(11):3904-11. PMID: 561657